| New pathway for qualification of novel methodologies in the European medicines agency. | |
| | |
MedLine Citation:
|
PMID: 21538915 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The European Medicines Agency (EMA) qualification process is a new, voluntary, scientific pathway leading to either a Committee for Medicinal Products for Human Use (CHMP) opinion or a Scientific Advice on innovative methods or drug development tools: (i) CHMP Qualification Opinion on the acceptability of a specific use of the proposed method, based on the assessment of submitted data and (ii) CHMP Qualification Advice on future protocols and methods for further method development towards qualification, based on the evaluation of the scientific rationale and on preliminary data submitted. The qualification procedure was established as a response to the drug development bottlenecks and inefficiencies, but also to the availability of new methodologies, not yet integrated in the drug development and clinical management paradigm. The qualification process addresses innovative methods developed by consortia, networks, public/private partnerships, learned societies or pharmaceutical industry. It is expected to facilitate communication between the scientific community and the regulators and to address challenges with the development and use of medicines. In this article, we will present an overview of the process and the up to now scientific advice working party (SAWP) experience. |
| | |
Authors:
|
Efthymios Manolis; Spiros Vamvakas; Maria Isaac |
Related Documents
:
|
21519265 - Comparison of video-assisted thoracoscopic surgery and open surgery in the management o... 20015895 - "silent virtuous teachers": anatomical dissection in taiwan. 21177405 - Managing invasive fungal infections: relying on clinical instincts or on a rational nav... 5125285 - Management of ingested foreign bodies in childhood. 20161685 - The normalization of deviance in healthcare delivery. 11259235 - A novel scheme for the reporting of adverse drug reactions. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-3-15 |
Journal Detail:
|
Title: Proteomics. Clinical applications Volume: - ISSN: 1862-8354 ISO Abbreviation: - Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-5-3 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101298608 Medline TA: Proteomics Clin Appl Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
Affiliation:
|
European Medicines Agency, London, UK. efthymios.manolis@ema.europa.eu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Is the time ripe for kidney tissue proteomics?
Next Document: Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for.